Canada appeals court backs Pfizer Lipitor patent

Thu Mar 20, 2008 8:18pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

NEW YORK (Reuters) - A Canadian appeals court has blocked the sale of a generic form of Pfizer Inc's (PFE.N: Quote) top-selling cholesterol fighter, Lipitor, by India's Ranbaxy Laboratories Ltd RANB.BO, overturning a lower court ruling, Pfizer said on Thursday.

The Federal Court of Appeal of Canada issued an order prohibiting approval of Ranbaxy's product in Canada until a Pfizer patent expires in July 2010, the company said.

The lower court had ruled that the enantiomer, or calcium salt, patent could not block Ranbaxy from seeking approval for a cheaper generic form of the world's biggest prescription medicine. Lipitor, known generically as atorvastatin calcium, has annual sales of about $12 billion.

Ranbaxy may seek a review of the decision by the Supreme Court of Canada, Pfizer said.

(Reporting by Bill Berkrot)